Merck Group

Merck and the European Molecular Biology Laboratory announce drug discovery collaboration

MerckMerck, a leading science and technology company, announced today that it has entered into a research collaboration focused on cancer metabolism with the European Molecular Biology Laboratory (EMBL), located in Heidelberg, Germany. The collaboration with EMBL is well-aligned with Merck's research and development (R&D) strategy in biopharma to complement its capabilities in early-stage oncology research with external innovation - particularly in specific modalities, including cancer metabolism.

The aim of the collaboration is to investigate mechanisms by which cancer cells generate energy and growth-enabling building blocks, which could ultimately deliver novel therapeutic targets, as well as biomarkers. The collaboration partners will make use of EMBL’s extended capacities and capabilities in the area of metabolomics.

"We are thrilled to enter into this new collaboration with EMBL. It will allow us to access state-of-the-art technologies and know-how, which complement our internal research efforts," said Andree Blaukat, Head of the Translational Innovation Platform Oncology at Merck. "It has become clear that cancer cells engage metabolic pathways to support growth and treatment resistance. Together with EMBL, we have the opportunity to characterize this phenomenon on the molecular level which will be instrumental for the development of novel therapies that target metabolic pathways in cancer."

During the three-year collaboration, EMBL will apply its unique expertise, combining modelling and bioinformatics with experimental approaches to uncover these metabolic pathways and shed light on their control mechanisms. EMBL will also utilize the cutting-edge equipment of its Genomics and Metabolomics Core Facilities to resolve the transcriptional and metabolic profiles of the samples for the study. "Together with Merck as an experienced partner in the field of oncology research, we are excited about the opportunity to apply our technologies to advance cancer research and pave the way for future drug development upon the discovery of novel targets," said Kiran Patil, group leader at EMBL. "Thanks to the cooperation with EMBL's technology transfer arm, we are now ready to start the project and looking forward to the upcoming years."

EMBL Enterprise Management Technology Transfer GmbH (EMBLEM) is the technology transfer arm of EMBL which transacts the collaboration on behalf of EMBL. By supporting scientists to enter collaborations like this one, EMBLEM underpins one of the core missions of EMBL: fostering interaction between academia and industry.

About EMBL
EMBL is Europe's flagship laboratory for the life sciences, with more than 80 independent groups covering the spectrum of molecular biology. EMBL is international, innovative and interdisciplinary - its 1600 employees, from many nations, operate across five sites: the main laboratory in Heidelberg, and outstations in Grenoble; Hamburg; Hinxton, near Cambridge (the European Bioinformatics Institute), and Monterotondo, near Rome. Founded in 1974, EMBL is an inter-governmental organisation funded by public research monies from its member states. The cornerstones of EMBL's mission are: to perform basic research in molecular biology; to train scientists, students and visitors at all levels; to offer vital services to scientists in the member states; to develop new instruments and methods in the life sciences and actively engage in technology transfer activities, and to integrate European life science research. Around 230 students are enrolled in EMBL’s International PhD programme. Additionally, the Laboratory offers a platform for dialogue with the general public through various science communication activities such as lecture series, visitor programmes and the dissemination of scientific achievements.

About EMBLEM
EMBL Enterprise Management Technology Transfer GmbH (EMBLEM) is an affiliate and the commercial arm of the European Molecular Biology Laboratory (EMBL). EMBLEM was founded in 1999 to facilitate and accelerate the transfer of innovative technology and know-how from EMBL to industry by way of collaboration, licensing, service provision and creation of spin-out companies.

About Merck
Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life - from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2014, Merck generated sales of € 11.3 billion in 66 countries.

Founded in 1668, Merck is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck, Darmstadt, Germany holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.

Most Popular Now

Boehringer Ingelheim increases acce…

Boehringer Ingelheim is announcing an expansion of its Intellectual Property (IP) enforcement policy. The IP enforcement policy had already been amended in 2007 by an eas...

Read more

AstraZeneca licenses Zurampic to Gr…

AstraZeneca today announced that it has entered into a licensing agreement with Grünenthal GmbH for the exclusive rights to Zurampic (lesinurad) in Europe and Latin Ameri...

Read more

Merck announces survey results expl…

Merck, a leading science and technology company, today announced survey results of 250 global biopharmaceutical executives on how their companies will manage new risks as...

Read more

Pfizer presents promising data from…

Pfizer Inc. (NYSE:PFE) today announced encouraging new data from a Phase 1/2 study of lorlatinib, the proposed generic name for PF-06463922, Pfizer's investigational, nex...

Read more

Bayer Science & Education Found…

Applications for the Bayer Science & Education Foundation's international scholarship programs are now being accepted for this year's round. In the academic sector, ambit...

Read more

Merck Accelerator expands its reach…

Merck, a leading science and technology company, has started this week the application period for the next round of its Accelerator programs in Darmstadt, Germany, and Na...

Read more

Promising treatment prospects for i…

In Switzerland alone, more than 5,700 women are diagnosed with breast cancer each year, and almost 1,400 of those affected die of the disease. In many very invasive forms...

Read more

AstraZeneca enters commercialisatio…

AstraZeneca today announced it has entered into a commercialisation agreement with Aspen Global Incorporated (AGI), part of the Aspen Group, for rights to its global anae...

Read more

Boehringer Ingelheim and Harvard sc…

Boehringer Ingelheim today announced it has established a research collaboration with the Harvard Stem Cell Institute's - Harvard Fibrosis Network to discover new ways of...

Read more

Call for Abstracts: DIA EuroMeeting…

29 - 31 March 2017, Glasgow, UK. The DIA EuroMeeting 2017 provides a platform for experts from all relevant disciplines within the entire healthcare development and acce...

Read more

FDA targets unlawful internet sales…

The U.S. Food and Drug Administration, in partnership with international regulatory and law enforcement agencies, announced that it took action this week against 4,402 we...

Read more

New class of protein could treat ca…

A protein designed by researchers at Georgia State University can effectively target a cell surface receptor linked to a number of diseases, showing potential as a therap...

Read more

Digest World Pharma Newsletter

Subscribe to our weekly Digest World Pharma Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]